Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
Leukemia
.
2022 May;36(5):1426-1428.
doi: 10.1038/s41375-021-01501-0.
Epub 2022 Jan 29.
Authors
Nadine Abdallah
1
,
David Murray
2
,
Angela Dispenzieri
1
,
Prashant Kapoor
1
,
Morie A Gertz
1
,
Martha Q Lacy
1
,
Suzanne R Hayman
1
,
Francis K Buadi
1
,
Wilson Gonsalves
1
,
Eli Muchtar
1
,
Nelson Leung
1
3
,
David Dingli
1
,
Taxiarchis Kourelis
1
,
Rahma Warsame
1
,
Moritz Binder
1
,
Robert A Kyle
1
,
S Vincent Rajkumar
1
,
Shaji Kumar
4
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
2
Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
3
Division of Nephrology, Mayo Clinic, Rochester, MN, USA.
4
Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
PMID:
35091659
PMCID:
PMC9061287
DOI:
10.1038/s41375-021-01501-0
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal*
Humans
Mass Spectrometry
Multiple Myeloma*
Substances
Antibodies, Monoclonal
daratumumab
Grants and funding
K12 CA090628/CA/NCI NIH HHS/United States
P30 CA015083/CA/NCI NIH HHS/United States
P50 CA186781/CA/NCI NIH HHS/United States